TOKYO (Reuters) – Japan’s Ministry of Public Health said on Friday it had agreed to buy 1. 4 million doses of Daiichi Sankyo’s updated COVID-19 vaccine.
The purchase is contingent upon approval of the vaccine formulated for the XBB. 1. 5 Omicron subvariant of the virus.
An earlier edition of the mRNA-based vaccine was approved in August as a booster, making it Japan’s first coronavirus vaccine.
During the pandemic, Japan basically relied on imports of mRNA-like vaccines developed through American drugmakers Pfizer and Moderna.
(Reporting via Rocky Swift; editing by Leslie Adler)
This site is powered by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.